Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 8/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495762 | 0.90 | LDHA (0.50) | P2RX3P2RX2LDHACYP3A4CYP2A6 | |
| SCHEMBL3071034 | 0.86 | BAZ2B (0.42) | BAZ2BP2RX3P2RX2NR1I2P2RX7 | |
| SCHEMBL3058393 | 0.86 | BAZ2B (0.48) | BAZ2BP2RX3P2RX2NR1I2P2RX7 | |
| SCHEMBL3066007 | 0.83 | KDM4E (0.48) | P2RX3P2RX2NR1I2LDHAKDM4C | |
| SCHEMBL24365557 | 0.83 | BAZ2B (0.60) | BAZ2BP2RX7KDM5AKDM4CKDM5B | |
| SCHEMBL31145174 | 0.83 | BAZ2B (0.60) | BAZ2BP2RX7KDM5AKDM4CKDM5B | |
| SCHEMBL3053335 | 0.82 | BAZ2B (0.44) | BAZ2BP2RX3P2RX2NR1I2P2RX7 | |
| SCHEMBL3053361 | 0.82 | LDHA (0.43) | P2RX3P2RX2NR1I2CYP2C9LDHA | |
| SCHEMBL3474997 | 0.81 | DHODH (0.54) | P2RX3P2RX2LDHAKDM4CCYP3A4 | |
| SCHEMBL12409679 | 0.81 | BAZ2B (0.65) | BAZ2BCNR1CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | BAZ2B 2384/4885P2RX3 1/4885P2RX2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.